Ranibizumab

LUCENTIS (ranibizumab injection) label

Macular Edema Following Retinal Vein Occlusion (RVO) (2.3)  LUCENTIS 0.5 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days). In the RVO clinical studies, patients received monthly injections of LUCENTIS for 6 months. In spite of being guided by optical coherence tomography and visual acuity re-treatment criteria, patients who were then...

Current perspectives on ranibizumab

BACKGROUND This review summarizes the Phase III studies addressing intravitreal ranibizumab treatment in patients with neovascular age-related macular degeneration (AMD), macular edema (ME) from retinal vein occlusion (RVO), and diabetic ME (DME). RESULTS The data from 12 major Phase III studies: six studies in patients with neovascular AMD, two studies in patients with ME from RVO, and four ...

Lucentis, INN-ranibizumab

Ranibizumab and bevacizumab for AMD.

n engl j med 365;23 nejm.org december 8, 2011 2237 developed during the study, only 44 had macrolide resistance (41%) (P<0.001). In my opinion, this is the correct method to evaluate resistance to macrolides because it compares the subjects of the two groups in whom colonization developed during the study period and not the whole group, as suggested by Hahn. Adequate data on resistance from the...

Foveal Exudative Macroaneurysm Treated with Intravitreal Ranibizumab

PURPOSE We report a case of a foveal macroaneurysm with long-standing macular edema in a rare location, successfully treated with intravitreal ranibizumab. METHODS We report the case of a 52-year-old man with left eye long-term visual loss due to macular edema caused by a retinal macroaneurysm, localized about 400 μm from the center of the fovea, and its response to 6 monthly ranibizumab intr...